CFTR modulators not linked to higher psychiatric symptom risk in CF
Study used multiple lines of investigation to evaluate several treatments
Written by |
CFTR modulators do not appear to increase the overall risk of depression, anxiety, or other neuropsychiatric symptoms in people with cystic fibrosis, a study has found. (Photo from iStock)
CFTR modulators, a class of medications that boost the activity of a faulty CFTR protein in people with cystic fibrosis (CF), do not appear to increase the overall risk of depression, anxiety, or other neuropsychiatric symptoms in people with the genetic disorder, a U.S. study has found.
The findings come amid reports of new or worsening neuropsychiatric symptoms in some people with CF after starting these medications.
Using several lines of investigation, researchers found no evidence that CFTR modulators directly cause such problems, either by unintentionally affecting other proteins in the brain or by changing the activity of CFTR itself in the brain.
Thus, researchers suggested, it may be worth considering “alternative hypotheses for the reported neuropsychiatric symptoms in some individuals with CF”
The study, “Evaluation of potential relationship between CFTR modulators, CFTR and neuropsychiatric symptoms in CF,” was published in the Journal of Cystic Fibrosis. It was funded by Vertex Pharmaceuticals, which markets all five CFTR modulators approved in the U.S. for CF. All but one of the study’s authors work for Vertex.
CFTR modulators have transformed CF care
CF is caused by genetic mutations that result in a faulty or missing CFTR protein, leading to the buildup of thick, sticky mucus in the lungs and other organs. Beyond affecting physical health, the condition can also take a toll on emotional wellness, with people with CF more likely to experience depression and anxiety than healthy individuals.
CFTR modulators have transformed CF care. Treatments such as the oral triple combinations Trikafta (elexacaftor/tezacaftor/ivacaftor) and Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) have improved lung function, reduced complications, and helped many people with CF enjoy a better quality of life.
Despite the benefits, however, a small proportion of people have reported new or worsening depression, anxiety, sleep problems, or brain fog after starting treatment. These symptoms typically appear within the first three months and, in some cases, have led people to interrupt or stop treatment.
These observations have led researchers to suggest two possible explanations: off-target effects, in which CFTR modulators unintentionally affect other proteins in the brain, or on-target effects, in which changes in the activity of the CFTR protein itself in the brain may contribute to these symptoms.
To investigate these possibilities, researchers in the U.S. first tested four individual drugs included in CFTR modulators — elexacaftor, tezacaftor, ivacaftor, and vanzacaftor — separately in laboratory and animal experiments.
Researchers examined trials of all 5 now-approved CFTR modulators
None of the drugs showed meaningful interactions with more than 65 proteins involved in brain function when tested at levels typically reached during treatment. Likewise, experiments in rats found no treatment-related changes in movement, rigidity, urination, or other responses that might suggest effects on the brain or nervous system.
The researchers then examined safety data from 72 Phase 2 and Phase 3 clinical trials that tested the five now-approved CFTR modulators in more than 6,000 people. Along with Trikafta and Alyftrek, these included the two-drug combinations Symdeko (tezacaftor/ivacaftor) and Orkambi (lumacaftor/ivacaftor), as well as Kalydeco (ivacaftor).
They looked at how often participants reported psychiatric problems, including depression, anxiety, changes in mood or behavior, and sleep disturbances.
Overall, although the difference was not statistically significant, psychiatric problems were reported at a lower rate among people taking CFTR modulators than in those receiving a placebo. Serious psychiatric problems and those leading participants to stop treatment were uncommon in both groups.
The picture was similar when the researchers looked at people receiving treatment in everyday clinical practice. Patient registries covering 8,967 people with CF in the U.S. and 1,028 in Germany who started Trikafta between late 2019 and 2021 showed no overall increase in diagnosed depression or anxiety when records from before and after treatment began were compared.
Multiple independent lines of investigation failed to show any evidence for off-target or on-target effects of [CFTR modulators] and/or CFTR function on neuropsychiatric symptoms.
These findings were supported by a separate review of 21 published studies involving more than 1,300 people with CF across eight countries who were also treated with Trikafta.
Of 12 studies examining depression, eight found no significant changes, three reported improvements, and one had mixed findings. Similarly, nine of 11 studies assessing anxiety found no significant changes, while two reported improvements. Among six studies examining sleep, three found no changes, two reported improvements, and one found no change or improvements depending on how sleep was measured.
Finally, an analysis of genetic information from approximately 1 million people across 24 studies and biobanks found no links between genetic mutations affecting CFTR function and 23 psychiatric conditions, including depression and anxiety.
“Multiple independent lines of investigation failed to show any evidence for off-target or on-target effects of [CFTR modulators] and/or CFTR function on neuropsychiatric symptoms,” the researchers concluded, while cautioning that the findings do not rule out more subtle effects on brain function or behavior that the experiments in the study may have missed.




Leave a comment
Fill in the required fields to post. Your email address will not be published.